World's Largest Resource for Cardiovascular Perfusion

Perfusion StaffingPerfusion Staffing
   +1 888-499-5672Login
Perfusion NewswireMain ZoneAdvantages of Off-Pump Coronary Artery Bypass Grafting in Long-Term Hemodialysis Patients: Multicenter Analysis

Advantages of Off-Pump Coronary Artery Bypass Grafting in Long-Term Hemodialysis Patients: Multicenter Analysis

Main Zone, Mobile Zone, Perfusion Zone

Objective: Long-term hemodialysis remains a major risk factor for coronary artery bypass grafting (CABG). Off-pump CABG (OPCAB) is expected to offer benefits for these highrisk patients; however, this issue has not been clarified. To elucidate the issue, we conducted a multicenter retrospective review of long-term hemodialysis patients who underwent on- or off-pump CABG.

Patients: Between January 1998 and December 2002, 53 hemodialysis patients underwent elective CABG at 14 centers. Nineteen patients underwent OPCAB, and 34 patients underwent conventional CABG (CCAB). Preoperative and perioperative variables, morbidity, and mortality were compared in the 2 groups. There were no significant differences in preoperative variables between the 2 groups.

Results: The length of intensive care unit (ICU) stay (3.7 versus 5.9 days), the amount of blood loss (668 versus 1100 mL), and the amount of red cell transfusion (4.7 versus 12.2 units) were less in the OPCAB group. The perioperative morbidity was significantly lower in the OPCAB group (0.0% versus 26.5%). The hospital mortality was not significant but was low in the OPCAB group (0% versus 14.7%, P = .079).

Conclusion: OPCAB significantly decreased blood loss, blood transfusion, ICU stay, and major perioperative morbidity compared with the values for CCAB. OPCAB may have advantages over CCAB in long-term hemodialysis patients.

Leave a Reply

You may also like

Main Zone, Mobile Zone, Perfusion Zone

Updated Treatment Algorithm of Pulmonary Arterial Hypertension

The current treatment algorithm may be divided into 3 main areas: 1) general measures, supportive therapy, referral strategy, acute vasoreactivity testing and chronic treatment with calcium channel blockers; 2) initial therapy with approved PAH drugs; and 3) clinical response to the initial therapy, combination therapy, balloon atrial septostomy, and lung transplantation. All three sections will be revisited highlighting information newly available in the past 5 years and proposing updates where appropriate.

Join TodayJoin Today